- Home
- SGMA vs KZIA Comparison
SGMA vs KZIA Comparison
Compare SGMA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMA
- KZIA
- Stock Information
- Founded
- SGMA 1993
- KZIA 1994
- Country
- SGMA United States
- KZIA Australia
- Employees
- SGMA N/A
- KZIA N/A
- Industry
- SGMA Electrical Products
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SGMA Technology
- KZIA Health Care
- Exchange
- SGMA Nasdaq
- KZIA Nasdaq
- Market Cap
- SGMA 16.3M
- KZIA 18.7M
- IPO Year
- SGMA 1994
- KZIA 1999
- Fundamental
- Price
- SGMA $1.54
- KZIA $3.02
- Analyst Decision
- SGMA
- KZIA Strong Buy
- Analyst Count
- SGMA 0
- KZIA 1
- Target Price
- SGMA N/A
- KZIA $20.00
- AVG Volume (30 Days)
- SGMA 76.8K
- KZIA 84.9K
- Earning Date
- SGMA 12-24-2024
- KZIA 12-27-2024
- Dividend Yield
- SGMA N/A
- KZIA N/A
- EPS Growth
- SGMA N/A
- KZIA N/A
- EPS
- SGMA N/A
- KZIA N/A
- Revenue
- SGMA $360,530,443.00
- KZIA $1,655,324.00
- Revenue This Year
- SGMA N/A
- KZIA $806.89
- Revenue Next Year
- SGMA N/A
- KZIA N/A
- P/E Ratio
- SGMA N/A
- KZIA N/A
- Revenue Growth
- SGMA N/A
- KZIA 248000.00
- 52 Week Low
- SGMA $1.50
- KZIA $1.90
- 52 Week High
- SGMA $6.47
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- SGMA 22.58
- KZIA 30.94
- Support Level
- SGMA $1.50
- KZIA $2.78
- Resistance Level
- SGMA $2.58
- KZIA $4.20
- Average True Range (ATR)
- SGMA 0.18
- KZIA 0.55
- MACD
- SGMA -0.10
- KZIA -0.13
- Stochastic Oscillator
- SGMA 3.10
- KZIA 9.92
About SGMA SigmaTron International Inc.
Sigmatron International Inc is an independent provider of electronic manufacturing services (EMS). It provides manufacturing and assembly services ranging from the assembly of individual components to the assembly and testing of box-build electronic products. The company manufactures products like printed circuit board assemblies, electro-mechanical subassemblies, and completely assembled (box-build) electronic products which are incorporated into finished products and sold in various industries, particularly industrial electronics, consumer electronics, and life sciences. In some instances, it manufactures and assembles the completed finished product for its customers. Geographically, the company derives maximum revenue from Mexico and the rest from the United States, China, and Vietnam.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.